NK vs. PGEN, ZIOP, CLLS, BLUE, ACLX, APGE, DNLI, IOVA, IMCR, and TWST
Should you be buying NantKwest stock or one of its competitors? The main competitors of NantKwest include Precigen (PGEN), ZIOPHARM Oncology (ZIOP), Cellectis (CLLS), bluebird bio (BLUE), Arcellx (ACLX), Apogee Therapeutics (APGE), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Immunocore (IMCR), and Twist Bioscience (TWST). These companies are all part of the "medical" sector.
Precigen (NASDAQ:PGEN) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.
Precigen presently has a consensus target price of $9.00, indicating a potential upside of 542.86%. Given NantKwest's higher probable upside, equities analysts plainly believe Precigen is more favorable than NantKwest.
Precigen received 155 more outperform votes than NantKwest when rated by MarketBeat users. Likewise, 67.08% of users gave Precigen an outperform vote while only 53.32% of users gave NantKwest an outperform vote.
In the previous week, Precigen had 1 more articles in the media than NantKwest. MarketBeat recorded 1 mentions for Precigen and 0 mentions for NantKwest. NantKwest's average media sentiment score of 1.87 beat Precigen's score of 0.00 indicating that Precigen is being referred to more favorably in the media.
33.5% of Precigen shares are held by institutional investors. Comparatively, 9.4% of NantKwest shares are held by institutional investors. 41.7% of Precigen shares are held by company insiders. Comparatively, 71.7% of NantKwest shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Precigen has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, meaning that its stock price is 161% more volatile than the S&P 500.
Precigen has a net margin of -1,781.72% compared to Precigen's net margin of -76,658.58%. Precigen's return on equity of -56.06% beat NantKwest's return on equity.
NantKwest has lower revenue, but higher earnings than Precigen. NantKwest is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.
Summary
Precigen beats NantKwest on 11 of the 17 factors compared between the two stocks.
Get NantKwest News Delivered to You Automatically
Sign up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NantKwest Competitors List
Related Companies and Tools
